Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
November 29, 2018 09:10 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation...
Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613
November 06, 2018 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mike Stelmah as...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
October 15, 2018 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, Inc. will be presenting at the BIO Investor Forum 2018 in San Francisco...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
October 09, 2018 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, its President...
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
August 16, 2018 10:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug...
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
August 13, 2018 11:15 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical...
Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613 in Pancreatic Cancer and Other Gastrointestinal Malignancies
July 13, 2018 09:15 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, July 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Eric Van Cutsem...
Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
June 14, 2018 10:12 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways...
Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
April 12, 2018 11:00 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, April 12, 2018 (GLOBE NEWSWIRE) --
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I...
Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer
November 16, 2017 09:25 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation...